Table 5.

Safety Outcomes Over 28 Days Following Treatment With Artemisinin-Based Combination Therapies

Selected Adverse Events of Any Severity	PROMOTE	TCC
	AL (n = 572)	AL (n = 201)	DP (n = 165)
Cough	247 (43.2%)	74 (36.8%)	64 (38.8%)
Diarrhea	50 (8.7%)	23 (11.4%)	27 (16.3%)
Anorexia	45 (7.9%)	4 (2.0%)	6 (3.6%)
Vomiting	39 (6.8%)	18 (9.0%)	8 (4.9%)
Malaise	35 (6.1%)	2 (1.0%)	2 (1.2%)
Neutropenia	156/515 (30.3%)	NA	NA
Anemia	29/522 (5.6%)	NA	NA
Thrombocytopenia	22/522 (4.2%)	NA	NA
Elevated alanine aminotransferase	32/488 (6.6%)	NA	NA

Data are presented as No. (%).

Abbreviations: AL, artemether-lumefantrine; DP, dihydroartemisinin-piperaquine; NA, not applicable; TCC, Tororo Child Cohort.